Axa S.A. Sells 51,128 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

AXA S.A. reduced its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 293,755 shares of the company's stock after selling 51,128 shares during the period. AXA S.A. owned about 0.20% of Denali Therapeutics worth $5,987,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after buying an additional 1,516 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after acquiring an additional 885 shares during the period. KBC Group NV grew its holdings in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after purchasing an additional 2,731 shares during the last quarter. AlphaQuest LLC lifted its holdings in shares of Denali Therapeutics by 177.1% in the 4th quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after purchasing an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in Denali Therapeutics by 32.2% during the 4th quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Stock Performance

DNLI traded down $0.04 during midday trading on Friday, hitting $14.39. The company had a trading volume of 1,367,985 shares, compared to its average volume of 1,092,248. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The company has a market capitalization of $2.09 billion, a PE ratio of -5.21 and a beta of 1.49. The firm's 50-day simple moving average is $14.27 and its 200-day simple moving average is $20.04.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the company posted ($0.68) earnings per share. As a group, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Analysts Set New Price Targets

DNLI has been the subject of several recent analyst reports. Wedbush decreased their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating for the company in a research report on Wednesday. Morgan Stanley began coverage on Denali Therapeutics in a research report on Friday, March 7th. They issued an "overweight" rating and a $33.00 target price on the stock. HC Wainwright decreased their price target on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday. Deutsche Bank Aktiengesellschaft began coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $31.00 price objective on the stock. Finally, Bank of America decreased their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $33.79.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.